ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · IEX Real-Time Price · USD
14.21
-0.45 (-3.07%)
At close: May 17, 2024, 4:00 PM
14.00
-0.21 (-1.48%)
After-hours: May 17, 2024, 4:03 PM EDT

ALX Oncology Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
0001.184.82.07
Revenue Growth (YoY)
----75.35%132.03%-
Cost of Revenue
0001.084.361.88
Gross Profit
0000.110.440.19
Selling, General & Admin
28.4829.0423.3914.813.312.6
Research & Development
141.898.460.1728.9616.3111.27
Operating Expenses
170.28127.4483.5643.7719.6213.87
Operating Income
-170.28-127.44-83.56-43.66-19.18-13.68
Interest Expense / Income
1.570.240.0100.020
Other Expense / Income
-11.04-4.26-0.081.840.010
Pretax Income
-160.81-123.42-83.48-45.5-19.21-13.69
Income Tax
00.06-0.020.240.030.05
Net Income
-160.81-123.48-83.46-45.74-19.24-13.73
Preferred Dividends
0005.24.033.67
Net Income Common
-160.81-123.48-83.46-50.94-23.27-17.4
Shares Outstanding (Basic)
4341401833
Shares Outstanding (Diluted)
4341401833
Shares Change
5.62%0.97%118.05%500.86%11.84%-
EPS (Basic)
-3.74-3.03-2.07-2.76-7.56-6.33
EPS (Diluted)
-3.74-3.03-2.07-2.76-7.56-6.33
Free Cash Flow
-131.64-90.65-68.77-38.32-14.6-13.84
Free Cash Flow Per Share
-3.06-2.23-1.71-2.07-4.75-5.03
Gross Margin
---9.05%9.09%9.05%
Operating Margin
----3693.99%-399.98%-662.02%
Profit Margin
----4309.81%-485.22%-841.90%
Free Cash Flow Margin
----3241.96%-304.46%-669.71%
EBITDA
-158.4-122.84-83.42-45.3-18.76-13.26
EBITDA Margin
----3832.23%-391.14%-641.27%
Depreciation & Amortization
0.840.340.050.20.430.43
EBIT
-159.24-123.18-83.47-45.5-19.19-13.69
EBIT Margin
----3849.32%-400.08%-662.12%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).